KRYS
Krystal Biotech, Inc.
NASDAQ · Healthcare · Biotechnology · US
$310.84
+1.90%Next report
Analyst consensus
- Next report date
- Feb 16, 2027
- EPS estimate
- $2.05
- Revenue estimate
- $134.5M
Latest reported
- Last report date
- Nov 2, 2026
- EPS actual
- $2.05
- EPS estimate
- $1.79
- Revenue actual
- $127.3M
- Revenue estimate
- $125.8M
Track record
Trailing twelve quarters
- EPS beats (12Q)
- 10
- EPS misses (12Q)
- 2
- EPS in line (12Q)
- 0
- Avg surprise (4Q)
- +12.7%
- Revenue beats (12Q)
- 3
Analyst ratings
Sell-side consensus
- Consensus
- Buy
- Price target
- $386
- PT range
- $361 – $412
- Analysts
- 5
5 Buy0 Hold0 Sell
Reported history
| Report date | EPS estimate | EPS actual | Surprise | Revenue actual |
|---|---|---|---|---|
| Nov 2, 2026 | $1.79 | $2.05 | Beat 14.53% | $127.3M |
| Aug 3, 2026 | $1.70 | $1.79 | Beat 5.29% | $119.2M |
| May 4, 2026 | $1.45 | $1.83 | Beat 26.21% | $116.4M |
| Feb 17, 2026 | $1.62 | $1.70 | Beat 4.94% | $107.1M |
| Feb 19, 2025 | $1.29 | $1.52 | Beat 17.83% | $91.1M |
| Feb 27, 2023 | -$1.39 | -$1.25 | Beat 10.07% | — |
| Feb 28, 2022 | -$0.76 | -$0.94 | Miss -23.68% | — |
| Mar 1, 2021 | -$0.55 | -$0.53 | Beat 3.64% | — |
| May 4, 2020 | -$0.42 | -$0.31 | Beat 26.19% | — |
| Mar 10, 2020 | -$0.33 | -$0.31 | Beat 6.06% | — |
| May 7, 2019 | -$0.35 | -$0.29 | Beat 17.14% | $583.0K |
| Mar 12, 2019 | -$0.24 | -$0.28 | Miss -16.67% | $1.0M |
Reported results against consensus at the time of each report · Surprise is computed from the estimate on record · Data as of Feb 16, 2027